Literature DB >> 21515678

Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization.

Juan Liu1, Purushottam Jha, Valeriy V Lyzogubov, Ruslana G Tytarenko, Nalini S Bora, Puran S Bora.   

Abstract

The present study investigated the interactions among the complement membrane attack complex (MAC), CCL2, and VEGF that occur in vivo during the development of choroidal neovascularization (CNV). We first investigated the sequential expression of MAC, CCL2, and VEGF during laser-induced CNV in C57BL/6 mice. Increased MAC deposition was detected at 1 h, CCL2 increased at 3 h, and VEGF was up-regulated at day 3 post-laser treatment. These results suggested that during laser-induced CNV, MAC, CCL2 and VEGF are formed and/or expressed in the following order: MAC → CCL2VEGF. To determine the cross-talk between MAC, CCL2, and VEGF during laser-induced CNV, neutralizing antibodies were injected both systemically and locally to block the bioactivity of each molecule. Blocking MAC formation inhibited CCL2 and VEGF expression and also limited CNV formation, whereas neutralization of CCL2 bioactivity did not affect MAC deposition; however, it reduced VEGF expression and CNV formation. When bioactivity of VEGF was blocked, CNV formation was significantly inhibited, but MAC deposition was not affected. Together, our results demonstrate that MAC is an upstream mediator and effect of MAC on the development of laser-induced CNV can be attributed to its direct effect on VEGF as well as its effect on VEGF that is mediated by CCL2. Understanding the interplay between immune mediators is critical to gain insight into the pathogenesis of CNV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515678      PMCID: PMC3121483          DOI: 10.1074/jbc.M111.226266

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  70 in total

1.  Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells.

Authors:  Jeong-Hyeon Sohn; Puran S Bora; Hye-Jung Suk; Hector Molina; Henry J Kaplan; Nalini S Bora
Journal:  Nat Med       Date:  2003-01-06       Impact factor: 53.440

Review 2.  Complement and its role in innate and adaptive immune responses.

Authors:  Jason R Dunkelberger; Wen-Chao Song
Journal:  Cell Res       Date:  2009-12-15       Impact factor: 25.617

Review 3.  Complement: an efficient sword of innate immunity.

Authors:  Günter Rambach; Reinhard Würzner; Cornelia Speth
Journal:  Contrib Microbiol       Date:  2008

Review 4.  Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia.

Authors:  Salomon Y Cohen
Journal:  Retina       Date:  2009-09       Impact factor: 4.256

5.  Complement factor H polymorphism and age-related macular degeneration.

Authors:  Albert O Edwards; Robert Ritter; Kenneth J Abel; Alisa Manning; Carolien Panhuysen; Lindsay A Farrer
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

6.  Complement factor H variant increases the risk of age-related macular degeneration.

Authors:  Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

Review 7.  Role and mechanism of action of complement in regulating T cell immunity.

Authors:  Jason R Dunkelberger; Wen-Chao Song
Journal:  Mol Immunol       Date:  2010-06-18       Impact factor: 4.407

Review 8.  Age-related macular degeneration: a leading cause of blindness.

Authors:  J G O'Shea
Journal:  Med J Aust       Date:  1996-11-18       Impact factor: 7.738

9.  Amyloid-beta up-regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: Another mechanism of complement activation in age-related macular degeneration.

Authors:  Jiying Wang; Kyoko Ohno-Matsui; Takeshi Yoshida; Noriaki Shimada; Shizuko Ichinose; Tetsuji Sato; Manabu Mochizuki; Ikuo Morita
Journal:  J Cell Physiol       Date:  2009-07       Impact factor: 6.384

Review 10.  Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.

Authors:  Susan B Bressler
Journal:  Ophthalmology       Date:  2009-10       Impact factor: 12.079

View more
  19 in total

Review 1.  Immunology of age-related macular degeneration.

Authors:  Jayakrishna Ambati; John P Atkinson; Bradley D Gelfand
Journal:  Nat Rev Immunol       Date:  2013-06       Impact factor: 53.106

2.  Topical application of a G-Quartet aptamer targeting nucleolin attenuates choroidal neovascularization in a model of age-related macular degeneration.

Authors:  Derek Leaderer; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Exp Eye Res       Date:  2015-09-12       Impact factor: 3.467

3.  Complement regulatory protein CD46 protects against choroidal neovascularization in mice.

Authors:  Valeriy Lyzogubov; Xiaobo Wu; Purushottam Jha; Ruslana Tytarenko; Michael Triebwasser; Grant Kolar; Paula Bertram; Puran S Bora; John P Atkinson; Nalini S Bora
Journal:  Am J Pathol       Date:  2014-07-11       Impact factor: 4.307

4.  The Complement Regulatory Protein CD46 Deficient Mouse Spontaneously Develops Dry-Type Age-Related Macular Degeneration-Like Phenotype.

Authors:  Valeriy V Lyzogubov; Puran S Bora; Xiaobo Wu; Leah E Horn; Ryan de Roque; Xeniya V Rudolf; John P Atkinson; Nalini S Bora
Journal:  Am J Pathol       Date:  2016-06-11       Impact factor: 4.307

5.  Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice.

Authors:  Vincent Lambert; Julie Lecomte; Sylvain Hansen; Silvia Blacher; Maria-Luz Alvarez Gonzalez; Ingrid Struman; Nor Eddine Sounni; Eric Rozet; Pascal de Tullio; Jean Michel Foidart; Jean-Marie Rakic; Agnès Noel
Journal:  Nat Protoc       Date:  2013-10-17       Impact factor: 13.491

6.  Characterization and validation of a chronic retinal neovascularization rabbit model by evaluating the efficacy of anti-angiogenic and anti-inflammatory drugs.

Authors:  Sandeep Kumar; John Quach; Nicholas Cook; Glenwood Gum; Vatsala Naageshwaran
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

7.  The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy.

Authors:  Leena Patel; Aswin Thaker
Journal:  J Pharmacol Pharmacother       Date:  2015 Jul-Sep

8.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 9.  Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation?

Authors:  Alasdair Warwick; Samir Khandhadia; Sarah Ennis; Andrew Lotery
Journal:  J Clin Med       Date:  2014-11-03       Impact factor: 4.241

10.  VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV.

Authors:  Hu Huang; Rachel Parlier; Ji-Kui Shen; Gerard A Lutty; Stanley A Vinores
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.